Back when Diabetic Investor first began we did so because back then many of the companies in this wacky world of ours weren’t covered by analysts and the few that were covered the analysts were clueless about diabetes. Today the first part has changed unfortunately the second part is alive and well. We mention this as recently we have read many analysts reports and kept wondering how such smart people could write glowing reports when we see things so much differently.
For example, we couldn’t understand why so many analysts had written off Dexcom (NASDAQ: DXCM) when Abbott . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.